Advertisement

Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis

  • Jacob E. Ollech
  • David T. RubinEmail author
  • Laura Glick
  • Roni Weisshof
  • Katia El Jurdi
  • Amanda Israel
  • Noa Krugliak Cleveland
  • Neil Hyman
  • Atsushi Sakuraba
  • Joel Pekow
  • Russell D. Cohen
  • Sushila R. Dalal
Original Article

Abstract

Background

Chronic antibiotic-refractory pouchitis (CARP) occurs in up to 15% of patients with ulcerative colitis (UC) following proctocolectomy with ileal pouch–anal anastomosis (IPAA).

Aim

To investigate the effectiveness of ustekinumab in the treatment of CARP.

Methods

This was a retrospective single-center study of UC patients with an IPAA, who subsequently developed CARP and received ustekinumab with standard Crohn’s disease (CD) dosing between 2016 and 2018. Patients with CD of the pouch were excluded. Demographic, clinical, and endoscopic data were collected. Outcomes included a change in the endoscopic subscore of the Pouchitis Disease Activity Index (PDAI), change in the ulcerated surface area, clinical response, and the number of bowel movements per 24 h.

Results

Twenty-four patients with CARP were included for analysis. Median follow-up time was 12.9 months (IQR 7.9-16). Twelve patients (50%) had a clinical response with the median number of bowel movements within 24 h decreasing from 8 (IQR, 5–12) to 6 (IQR, 5–8) P = 0.002. Thirteen patients had pouchoscopies available post-ustekinumab treatment. In these patients, the median endoscopic subscore of the PDAI decreased from 5 (IQR, 3–6) to 4 (IQR, 2–5), P = 0.016. Likewise, among these thirteen patients, nine (69%) had an ulcerated surface area > 10% before ustekinumab treatment; after treatment with ustekinumab, only four patients (31%) still had an ulcerated surface area of > 10%.

Conclusions

This is the largest study of ustekinumab treatment for patients with chronic antibiotic-refractory pouchitis. We found that ustekinumab therapy led to the improvement in clinical and endoscopic endpoints.

Keywords

Pouchitis Ustekinumab Ileal pouch–anal anastomosis PDAI 

Notes

Author's contribution

JEO, DTR, and SRD conceived and designed the study. JEO, LG, RW, AI, KEJ, and NCK contributed to the acquisition of data. JEO, DTR, SRD, RW, RDC, AS, JP, and NH contributed to the analysis and interpretation of data. All authors were involved in drafting the article or revising it critically for important intellectual content. All authors approved the final manuscript to be submitted.

Funding

This work received no outside funding.

Compliance with ethical standards

Conflict of interest

JEO, RW, KEJ, AI, NKC, and NH have no relevant disclosures. DTR is a consultant and has received grant support from Abbvie, Merck & Co., Janssen, Takeda, and Pfizer. AS has received funding from AbbVie, Celltrion, and Takeda. JP has received grants from Takeda and Abbvie and serves as a consultant for Verastem. He was on the advisory board for Pfizer and Janssen. RDC is a consultant at Abbvie, Celgene, Janssen, Pfizer, Takeda, and UCB Pharma. SD has received grant support from Pfizer. No funding or sponsorship was received for this study or publication of this article.

References

  1. 1.
    Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228–1235.  https://doi.org/10.1038/ajg.2012.127.CrossRefGoogle Scholar
  2. 2.
    Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–440.  https://doi.org/10.1080/00365520802600961.CrossRefGoogle Scholar
  3. 3.
    Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology. 2003;124:1636–1650. Epub 2003/05/23 PubMed PMID: 12761722.CrossRefGoogle Scholar
  4. 4.
    Barnes EL, Herfarth HH, Sandler RS, et al. Pouch-Related Symptoms and Quality of Life in Patients with Ileal Pouch-Anal Anastomosis. Inflamm Bowel Dis. 2017;23:1218–1224.  https://doi.org/10.1097/mib.0000000000001119.CrossRefGoogle Scholar
  5. 5.
    Heuschen UA, Allemeyer EH, Hinz U, et al. Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up. Dis Colon Rectum. 2002;45:776–786. discussion 86–88.CrossRefGoogle Scholar
  6. 6.
    Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis. Am J Gastroenterol. 2015;110:881–887.  https://doi.org/10.1038/ajg.2015.129.CrossRefGoogle Scholar
  7. 7.
    Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649–670.  https://doi.org/10.1093/ecco-jcc/jjx008.CrossRefGoogle Scholar
  8. 8.
    Dalal RL, Shen B, Schwartz DA. Management of Pouchitis and Other Common Complications of the Pouch. Inflamm Bowel Dis. 2018;24:989–996.  https://doi.org/10.1093/ibd/izy020.CrossRefGoogle Scholar
  9. 9.
    Bar F, Kuhbacher T, Dietrich NA, et al. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther. 2018;47:581–587.  https://doi.org/10.1111/apt.14479.CrossRefGoogle Scholar
  10. 10.
    Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375:1946–1960.  https://doi.org/10.1056/nejmoa1602773.CrossRefGoogle Scholar
  11. 11.
    Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409–415. Epub 1994/05/01 PubMed PMID: 8170189.CrossRefGoogle Scholar
  12. 12.
    Weaver KN, Gregory M, Syal G, et al. Ustekinumab Is Effective for the Treatment of Crohn’s Disease of the Pouch in a Multicenter Cohort. Inflamm Bowel Dis. 2018;.  https://doi.org/10.1093/ibd/izy302.Google Scholar
  13. 13.
    Samaan MA, Shen B, Mosli MH, et al. Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointest Endosc. 2018;88:360–369 e2.  https://doi.org/10.1016/j.gie.2018.04.2330.CrossRefGoogle Scholar
  14. 14.
    Huguet M, Pereira B, Goutte M, et al. Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn’s Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis. Inflamm Bowel Dis. 2018;24:261–268.  https://doi.org/10.1093/ibd/izx049.CrossRefGoogle Scholar
  15. 15.
    Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, Peyrin-Biroulet L, Van-Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C. Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Study. Presented at ACG 2018.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jacob E. Ollech
    • 1
  • David T. Rubin
    • 1
    Email author
  • Laura Glick
    • 1
  • Roni Weisshof
    • 1
  • Katia El Jurdi
    • 1
  • Amanda Israel
    • 1
  • Noa Krugliak Cleveland
    • 1
  • Neil Hyman
    • 1
  • Atsushi Sakuraba
    • 1
  • Joel Pekow
    • 1
  • Russell D. Cohen
    • 1
  • Sushila R. Dalal
    • 1
  1. 1.University of Chicago Medicine, Inflammatory Bowel Disease CenterChicagoUSA

Personalised recommendations